Evercore ISI Group Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Liisa Bayko has maintained an Outperform rating on Kiniksa Pharmaceuticals (NASDAQ:KNSA) and increased the price target from $25 to $30.
April 24, 2024 | 5:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evercore ISI Group has reaffirmed its Outperform rating on Kiniksa Pharmaceuticals and raised its price target from $25 to $30.
The increase in price target by a reputable analyst firm like Evercore ISI Group typically signals a strong bullish sentiment on the stock, suggesting that the firm believes Kiniksa Pharmaceuticals has strong future prospects. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100